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Lactate is produced from glucose by adipose tissue. In this issue of Cell Metabolism, Ahmed et al. (2010)
show that the metabolite is involved in the antilipolytic effect of insulin, providing a new link between fat
and carbohydrate metabolism.Adipose tissue is the body’s largest
energy reservoir and a major source of
metabolic fuel. In periods of food supply,
energy is stored as triglycerides, whereas
in periods of energy demand, triglycerides
are hydrolyzed to release nonesterified
fatty acids into the bloodstream. Adipose
tissue lipolysis is an exquisitely controlled
process (Figure 1). Catecholamines, natri-
uretic peptides, and insulin are consid-
ered to represent the major regulators
of lipolysis in humans (Lafontan and
Langin, 2009). When catecholamines, the
hormone adrenaline and the neurotrans-
mitter noradrenaline, bind b-adrenergic
receptors, seven-transmembrane domain
receptors coupled to stimulatory Gs pro-
teins, there is an activation of adenylylcy-
clase leading to a rise in intracellular
cAMP levels. Activated protein kinase A
phosphorylates the lipid droplet protein
perilipin and hormone-sensitive lipase,
thereby promoting hydrolysis of triglycer-
ides. Atrial and brain natriuretic peptides
stimulate lipolysis via activation of type
A natriuretic peptide receptor but through
a different intracellular route which in-
volves cGMP and protein kinase G. Insulin
is the major antilipolytic hormone in the
fed state acting to limit release of fatty
acids. The signal transduction pathway
results in activation of phosphodiesterase
3B, which hydrolyzes cAMP into inactive
50AMP and thereby diminishes protein
kinase A-mediated phosphorylations.
Besides insulin, a large number of antili-
polytic receptors negatively coupled to
adenylylcyclase through inhibitory Gi pro-
teins have been described. With the ex-
ception of the a2-adrenergic receptors
stimulated by catecholamines, most242 Cell Metabolism 11, April 7, 2010 ª2010ligands for these receptors are thought
to act in a paracrine manner, and their
physiological roles remain elusive. Re-
cently, several new Gi protein-coupled
receptors with high expression in adipose
tissue have been identified. The endoge-
nous ligands of these previously orphan
receptors may be metabolites. The first
to be characterized was GPR109A, the
receptor for nicotinic acid or niacin, an
old lipid-lowering drug (Ahmed et al.,
2009). The ketone body, b-hydroxybuty-
rate, specifically activates the receptor
at concentrations observed in serum
during fasting. The receptor for L-lactate,
GPR81, is closely related to the b-hydrox-
ybutyrate receptor. In the physiological
concentration range, L-lactate inhibits
lipolysis in adipocytes from humans,
mice, and rats (Ahmed et al., 2009). In
the present issue of Cell Metabolism,
Ahmed et al. provide compelling evidence
for an involvement of lactate and GPR81
in the antilipolytic action of insulin (Ahmed
et al., 2010).
As lactate is produced in large amounts
by skeletal muscle during anaerobic
physical exercise, it was first hypothe-
sized that the metabolite provides a nega-
tive feedback when other factors potently
stimulate lipolysis. The rationale could be
to limit fatty acid release during times
when glycolysis rates exceed mitochon-
drial respiration rates in skeletal muscle.
However, Ahmed et al. found no evidence
for lactate-mediated inhibition of lipolysis
during various conditions of intensive
exercise in mice (Ahmed et al., 2010),
thus confirming earlier data in humans
(Trudeau et al., 1999). It therefore appears
that lactate produced by skeletal muscleElsevier Inc.during physical exercise does not act on
adipose tissue. Early studies revealed
that fat cells produced lactate in signifi-
cant amounts, especially when glucose
uptake is stimulated by insulin or during
a1-adrenergic receptor-mediated cate-
cholamine stimulation (DiGirolamo et al.,
1992; Faintrenie and Geloen, 1996; Hag-
strom et al., 1990). In mice, increased
plasma glucose level was accompanied
by more release of lactate and less of
fatty acids by adipose tissue (Ahmed
et al., 2010). The antilipolytic effect was
blunted in GPR81-deficient mice despite
a similar increase in lactate production.
This observation could be reproduced
in vitro on adipose tissue. Insulin-induced
decrease of cAMP levels and inhibition of
lipolysis were both diminished in adipose
tissue lacking GPR81. The authors also
analyzed the impact of GPR81 deficiency
on body composition and insulin sensi-
tivity. Compared to wild-type mice, ani-
mals without GPR81 gained less weight
during high-fat diet without modification
in glucose tolerance. This study offers
a new paradigm for insulin antilipolytic
action, revealing an unappreciated link
between glucid and lipid metabolic path-
ways. Besides the now-classical intracel-
lular route leading to phosphodiesterase
3B activation, the decrease in cAMP
levels may also result from lactate activa-
tion of GPR81 and subsequent inhibition
of adenylylcyclase (Figure 1). Further-
more, it shows that lactate chiefly acts
on adipose tissue metabolism in an auto-
crine/paracrine manner.
The new roles of lactate and GPR81
are raising a flurry of questions and will
undoubtedly foster research in different
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Figure 1. Control of Human Adipocyte Lipolysis
Binding of catecholamines to Gs protein-coupled b1/2-adrenoceptors stimulates cAMP production by
adenylyl cyclase (AC) and activates protein kinase A (PKA) while, conversely, stimulation of Gi protein-
coupled a2-adrenergic receptors (data not shown) reduces cAMP and PKA activation. Insulin favors
cAMP degradation through activation of phosphatidylinositol-3 phosphate kinase (PI3-K) and protein
kinase B (PKB) and stimulation of phosphodiesterase 3B (PDE-3B) activity. Natriuretic peptides promote
cGMP accumulation and protein kinase G (PKG) activation. PKA and PKG phosphorylate hormone-sensi-
tive lipase (HSL) and perilipin A (PLINA). Adipose triglyceride lipase (ATGL) and monoglyceride lipase
(MGL) are also participating in the hydrolysis of triglycerides. Ahmed et al. (2010), in this issue, propose
a new pathway shown by blue arrows involving the glucose transporter GLUT4; glycolysis-mediated
lactate production; and the Gi protein-coupled lactate receptor, GPR81, in insulin-induced antilipolytic
effect.
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Previewsdirections. There are several queries
related to the physiological and patholog-
ical importance of this new pathway at
the interface between fat and carbohy-
drate metabolism. Demonstration of the
relevance in human physiology is now
warranted. Important species differences
have been described in the control of
lipolysis (Lafontan and Langin, 2009).
The natriuretic peptide pathway is a lipo-
lytic pathway operational in humans in
various conditions but not in rodents. As
the second messenger of this pathway is
cGMP, it is likely that lactate does not
inhibit natriuretic peptide-induced lipol-
ysis. Moreover, do catecholamines inhibit
lipolysis not only through a2-adrenergic
receptor activation but also via a1-adren-
ergic receptor-stimulated production of
lactate, and does this latter process
play a role in the crosstalk between cate-
cholamines and insulin (Faintrenie and
Geloen, 1996)? The involvement of lactate
in insulin-mediated antilipolysis implies
stimulation of glucose uptake by insulin.Therefore, alteration in the adipose tissue
expression of the insulin-sensitive glu-
cose transporter GLUT4 as reported in
obesity and type 2 diabetes (Shepherd
and Kahn, 1999) can be expected to result
in diminution of insulin inhibition of lipol-
ysis. However, insulin injection led to
a normal suppression of fatty acid levels
in mice with specific adipose tissue abla-
tion of GLUT4 (Abel et al., 2001). In addi-
tion, it needs to be assessed whether
alteration of adipose tissue insulin-stimu-
lated glucose uptake, i.e., development
of local insulin resistance, contributes to
diminished insulin-mediated antilipolysis
and enhanced fatty acid release that
may lead to systemic insulin resistance
and dyslipidemia. No difference in glu-
cose and insulin tolerance was observed
between wild-type and GPR81-deficient
mice fed high-fat diet. As the decrease
in insulin-mediated antilipolysis could
lead to sustained plasma nonesterified
fatty acid levels, a deterioration of insulin
sensitivity was expected. However, theCell Metabolismlower weight and supposedly fat mass of
GPR81-deficient mice may have counter-
balanced the expected increase of insulin
resistance. Understanding the influence
of GPR81 inactivation on insulin sensi-
tivity is also important in a pharmacolog-
ical perspective. GPR81 shows a highly
restricted tissue distribution. It therefore
constitutes a target amenable to drug
development to limit deleterious fatty
acid release from adipose tissue and
improve the metabolic profile of dyslipi-
demic patients. In that respect, GPR81
may prove a better therapeutic target
than GPR109A, as the expression of the
nicotinic acid receptor in Langerhans cells
has impaired the widespread use of nico-
tinic acid due to upper-body skin flushing.
In a previous issue of Cell Metabolism,
a cell-cycle protein was shown to be a
regulator of adipose triglyceride lipase
(Yang et al., 2010). A classic of biochem-
istry textbooks, lipolysis proves an ever-
revisited pathway.
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